[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:diffuse-intrinsic-pontine-glioma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":180,"states":189},"Diffuse Intrinsic Pontine Glioma",28,27,[8,16,23,29,36,42,48,54,60,66,72,79,85,90,96,102,108,114,120,126,132,138,144,150,156,162,168,174],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07680439","Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).",[12],"Phase 2","RECRUITING","2026-08-26T02:17:02.694423Z","2026-07-05T03:45:20.443469Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04837547","PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy",[20],"Phase 1","2026-08-26T02:19:06.150683Z","2026-07-05T03:45:20.247004Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06838676","ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas",[12],"2026-08-26T02:15:02.712396Z","2026-06-16T05:54:07.925383Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06333899","Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion",[33],"Early Phase 1","2026-08-26T02:19:00.742020Z","2026-05-05T02:43:29.136961Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04943848","rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG",[20],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:28.983532Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04655404","A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion",[33],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.502559Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06894979","Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma",[20],"2026-08-03T00:59:21.983893Z","2026-07-05T05:32:16.705849Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06305910","CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG\u002FDIPG in Children and Young Adults",[20],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:29.586016Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05096481","PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:29.390899Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05843253","Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant",[12],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:29.388169Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":77,"content_modified":78},"NCT05099003","A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)",[76],"Phase 1\u002FPhase 2","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:28.532137Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05009992","Combination Therapy for the Treatment of Diffuse Midline Gliomas",[12],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:28.301737Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":34,"content_modified":89},"NCT05004116","A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer",[76],"2026-05-05T02:43:27.261412Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06624371","Atovaquone Combined With Radiation in Children With Malignant Brain Tumors",[20],"2026-08-26T02:15:13.282904Z","2026-05-05T02:35:31.758752Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05278208","Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors",[76],"2026-08-26T02:18:21.216897Z","2026-07-24T01:27:14.928126Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06161974","Study of Olutasidenib and Temozolomide in HGG",[12],"2026-08-26T02:17:51.502023Z","2026-07-05T05:32:16.747418Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06639607","PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma\u002FHigh-grade Glioma and Recurrent Diffuse Midline Glioma\u002FHigh-grade Glioma, Medulloblastoma, and Ependymoma",[76],"2026-08-03T00:58:26.564367Z","2026-07-05T05:32:16.689130Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06465199","Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas",[76],"2026-08-26T02:15:58.452248Z","2026-06-16T05:54:07.918391Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05956821","Treatment of Relapsed\u002FRefractory Intracranial Glioma in Patients Under 22 Years of Age",[76],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:28.959675Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT04185038","Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\u002FDiffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors",[20],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:28.903254Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT02390752","Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...",[20],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.488578Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT04870944","CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma",[76],"2026-08-03T02:31:11.254845Z","2026-05-05T02:43:27.478011Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT05553041","18F-Fluciclovine PET-MRI in High-grade Glioma",[33],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.962637Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06140719","xPedite: A Study to Expedite DIPG and DMG Research",[],"2026-08-26T02:18:15.214990Z","2026-05-13T02:55:06.417556Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT03101813","International Diffuse Intrinsic Pontine Glioma (DIPG)\u002FDiffuse Midline Glioma (DMG) Registry and Repository",[],"2026-08-26T02:16:44.178623Z","2026-05-13T02:55:06.107366Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT01106794","Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma",[],"2026-08-26T02:17:52.450442Z","2026-05-13T02:55:06.067751Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT05839379","Targeted Pediatric High-Grade Glioma Therapy",[],"2026-08-26T02:18:20.384845Z","2026-05-13T02:55:06.380433Z",{"nct_id":175,"title":176,"phases":177,"status":178,"updated_at":166,"content_modified":179},"NCT06946680","IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)",[20],"NOT_YET_RECRUITING","2026-05-29T15:36:40.176961Z",[181,185],{"biomarker":182,"count":183,"slug":184},"H3 K27M Variant",7,"h3-k27m-variant",{"biomarker":186,"count":187,"slug":188},"Histone H3 Lysine 28",3,"histone-h3-lysine-28",[190,194,198,202,206,209,212,215,219,223,227,231,234,237,241,245,248,251,255,258,261,264],{"state":191,"count":192,"slug":193},"Pennsylvania",16,"pennsylvania",{"state":195,"count":196,"slug":197},"Ohio",14,"ohio",{"state":199,"count":200,"slug":201},"Washington",13,"washington",{"state":203,"count":204,"slug":205},"District of Columbia",12,"district-of-columbia",{"state":207,"count":204,"slug":208},"Illinois","illinois",{"state":210,"count":204,"slug":211},"North Carolina","north-carolina",{"state":213,"count":204,"slug":214},"Texas","texas",{"state":216,"count":217,"slug":218},"Colorado",11,"colorado",{"state":220,"count":221,"slug":222},"Massachusetts",10,"massachusetts",{"state":224,"count":225,"slug":226},"Florida",9,"florida",{"state":228,"count":229,"slug":230},"Michigan",8,"michigan",{"state":232,"count":229,"slug":233},"Missouri","missouri",{"state":235,"count":183,"slug":236},"California","california",{"state":238,"count":239,"slug":240},"Georgia",6,"georgia",{"state":242,"count":243,"slug":244},"Alabama",5,"alabama",{"state":246,"count":243,"slug":247},"Minnesota","minnesota",{"state":249,"count":243,"slug":250},"New York","new-york",{"state":252,"count":253,"slug":254},"Indiana",4,"indiana",{"state":256,"count":253,"slug":257},"Maryland","maryland",{"state":259,"count":253,"slug":260},"Tennessee","tennessee",{"state":262,"count":187,"slug":263},"New Jersey","new-jersey",{"state":265,"count":187,"slug":266},"Utah","utah"]